Neutrolis Inc. is a clinical-stage biotechnology firm that specializes in developing innovative therapies aimed at autoimmune and inflammatory diseases. The company's unique approach focuses on targeting Neutrophil Extracellular Traps (NETs), which are implicated in tissue damage and chronic inflammation associated with several immune-mediated disorders, such as lupus and dry eye disease, as well as severe complications from conditions like COVID-19.
The exDNASE™ platform is Neutrolis’s proprietary technology designed to engineer enzymes specifically for the degradation of Neutrophil Extracellular Traps (NETs). This platform is pivotal in developing therapies that can mitigate the damaging effects of overactive neutrophils in autoimmune and inflammatory diseases.
The exDNASE™ platform addresses the root cause of tissue damage and chronic inflammation caused by NETs, providing targeted treatment options that improve patient outcomes without compromising immune function.
The primary issues addressed include the chronic inflammation and tissue damage caused by excessive NETs in autoimmune disorders, and the inadequate efficacy of current immune-suppressive treatments.